XML 65 R13.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Goodwill and Intangible Assets | 6 Months Ended
--- | ---
Dec. 31, 2019
Goodwill And Intangible Assets Disclosure [Abstract] |
Goodwill and Intangible Assets |
(6) | GOODWILL AND INTANGIBLE ASSETS
Goodwill The Company has recorded goodwill of $408.1 from the acquisitions of Counsyl that was completed on July 31, 2018, Assurex that was completed on August 31, 2016, Sividon Diagnostics GmbH (“Sividon”) that was completed on May 31, 2016, Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG (the “Clinic”) that was completed on February 27, 2015, Crescendo Bioscience, Inc. that was completed on February 28, 2014 and Rules-Based Medicine, Inc. that was completed on May 31, 2011. Of this goodwill, $351.3 relates to the Company’s diagnostic segment and $56.8 relates to the other segment. The following summarizes changes to the goodwill balance for the six months ended December 31, 2019:
|  | Carrying amount |
Ending balance June 30, 2019 |  | $ | 417.2 |
Goodwill allocated to assets held for sale |  |  | (7.3 | )
Goodwill impairment charge |  |  | (1.3 | )
Translation adjustments |  |  | (0.5 | )
Ending balance December 31, 2019 |  | $ | 408.1 |
See Note 18 for further discussions regarding goodwill allocated to assets held for sale. Intangible Assets Intangible assets primarily consist of amortizable assets of purchased licenses and technologies, customer relationships, and trade names as well as non-amortizable intangible assets of in-process technologies and research and development. The following summarizes the amounts reported as intangible assets:
|  | Gross |  |  |  |  |  |  |  |  |
|  | Carrying |  |  | Accumulated |  |  |  |  |
|  | Amount |  |  | Amortization |  |  | Net |
At December 31, 2019: |  |  |  |  |  |  |  |  |  |  |  |
Purchased licenses and technologies |  | $ | 815.2 |  |  | $ | (186.8 | ) |  | $ | 628.4 |
Customer relationships |  |  | 4.7 |  |  |  | (4.0 | ) |  |  | 0.7 |
Trademarks |  |  | 3.0 |  |  |  | (1.3 | ) |  |  | 1.7 |
Total amortized intangible assets |  |  | 822.9 |  |  |  | (192.1 | ) |  |  | 630.8 |
In-process research and development |  |  | 22.7 |  |  |  | — |  |  |  | 22.7 |
Total unamortized intangible assets |  |  | 22.7 |  |  |  | — |  |  |  | 22.7 |
Total intangible assets |  | $ | 845.6 |  |  | $ | (192.1 | ) |  | $ | 653.5 |
|  | Gross |  |  |  |  |  |  |  |  |
|  | Carrying |  |  | Accumulated |  |  |  |  |
|  | Amount |  |  | Amortization |  |  | Net |
At June 30, 2019: |  |  |  |  |  |  |  |  |  |  |  |
Purchased licenses and technologies |  | $ | 815.7 |  |  | $ | (156.6 | ) |  | $ | 659.1 |
Customer relationships |  |  | 4.6 |  |  |  | (3.8 | ) |  |  | 0.8 |
Trademarks |  |  | 3.0 |  |  |  | (1.2 | ) |  |  | 1.8 |
Total amortized intangible assets |  |  | 823.3 |  |  |  | (161.6 | ) |  |  | 661.7 |
In-process research and development |  |  | 23.0 |  |  |  | — |  |  |  | 23.0 |
Total unamortized intangible assets |  |  | 23.0 |  |  |  | — |  |  |  | 23.0 |
Total intangible assets |  | $ | 846.3 |  |  | $ | (161.6 | ) |  | $ | 684.7 |
The Company recorded amortization expense during the respective periods for these intangible assets as follows:
|  | Three months ended |  |  | Six months ended |
|  | December 31, |  |  | December 31, |
|  | 2019 |  |  | 2018 |  |  | 2019 |  |  | 2018 |
Amortization of intangible assets |  | $ | 15.2 |  |  | $ | 15.4 |  |  | $ | 30.5 |  |  | $ | 28.8 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration